AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38116040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dorsal penile nerve block (DPNB) with sedation
Number of subjects: 70
Study 38116040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound-guided DPNB)
Number of subjects: 70
Study 38116137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoxic dose escalation to 75 Gy in 30 fractions with concurrent bevacizumab (BEV)
Number of subjects: 10
Study 38116137 — intervention group
Group type: COMPARATOR
Intervention: Reference plan (not specified in detail)
Number of subjects: 10
Study 38116535 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted percutaneous coronary intervention (RA-PCI) using the CorPath GRX Vascular Robotic System
Number of subjects: 21
Study 38116638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirbanibulin 1% ointment applied once daily for 5 consecutive days
Number of subjects: 702
Study 38116638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirbanibulin 1% ointment
Number of subjects: 702
Study 38116642 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg) administered intravenously 16 times over 6 months
Number of subjects: 139
Study 38116658 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected lymph nodes
Number of subjects: 0
Study 38116658 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38116670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting postoperative soiling
Number of subjects: 601
Study 38116674 — intervention group
Group type: EXPERIMENTAL
Intervention: Transection of the pulmonary branches of the vagus nerve
Number of subjects: 116
Study 38116674 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control group)
Number of subjects: 116
Study 38116682 — intervention group
Group type: EXPERIMENTAL
Intervention: Kynurenine/tryptophan above 0.067 µM/µM
Number of subjects: 146
Study 38116682 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC18:2/PCa36:2 below the cut-off 0.084 µM/µM
Number of subjects: 146
Study 38116682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexadecanoylcarnitine below 0.093 µM
Number of subjects: 146
Study 38117424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed phenotype ATTR amyloidosis
Number of subjects: 1185
Study 38117449 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive (n=52)
Number of subjects: 102
Study 38117449 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (n=50)
Number of subjects: 102
Study 38117500 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-delivered meals
Number of subjects: 243
Study 38117500 — intervention group
Group type: COMPARATOR
Intervention: Drop-shipped frozen meals
Number of subjects: 243
Study 38117499 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nudges (9 different nudge letters)
Number of subjects: 964870
Study 38117499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 964870
Study 38117499 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nudges (cardiovascular benefits letter)
Number of subjects: 964870
Study 38117499 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nudges (repeated letter)
Number of subjects: 964870
Study 38117526 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-07038124, 0.01%, topical ointment once daily for 6 weeks
Number of subjects: 104
Study 38117526 — intervention group
Group type: COMPARATOR
Intervention: Vehicle, topical ointment once daily for 6 weeks
Number of subjects: 104
Study 38117527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 3.75 mg
Number of subjects: 616
Study 38117527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 38117554 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure cohort (n=30)
Number of subjects: 60
Study 38117554 — intervention group
Group type: COMPARATOR
Intervention: Food-secure cohort (n=30)
Number of subjects: 60
Study 38117578 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0
Study 38117578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 0
Study 38118022 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline PEP (200 mg taken within 72 hours after condomless sex)
Number of subjects: 449
Study 38118022 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 449
Study 38118022 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline PEP
Number of subjects: 449
Study 38118246 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf only (C)
Number of subjects: 105
Study 38118246 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh and calf (TC)
Number of subjects: 105
Study 38118246 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttock and calf (BC)
Number of subjects: 105
Study 38118246 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttock, thigh, and calf (BTC)
Number of subjects: 105
Study 38118246 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 105
Study 38118249 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT543 35 mg
Number of subjects: 56
Study 38118249 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT543 45 mg
Number of subjects: 56
Study 38118249 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT543
Number of subjects: 56
Study 38118406 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cells targeting CD19 and B cell maturation antigen (BCMA)
Number of subjects: 0
Study 38118406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CART-BCMA and CART-19
Number of subjects: 0
Study 38122865 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg
Number of subjects: 81
Study 38122865 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat
Number of subjects: 81
Study 38122893 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE MASL
Number of subjects: 8
Study 38122893 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE MASH
Number of subjects: 8
Study 38122893 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE MASL and OBE MASH
Number of subjects: 8
Study 38123024 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber, n = 39, for 6 weeks
Number of subjects: 209
Study 38123024 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 49, for 6 weeks
Number of subjects: 209
Study 38123124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 88
Study 38123352 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg + Itraconazole
Number of subjects: 43
Study 38123352 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg + Mefenamic acid
Number of subjects: 43
Study 38123352 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat 300 mg + Rifampin
Number of subjects: 43
Study 38123459 — intervention group
Group type: EXPERIMENTAL
Intervention: SLEDAI-2K score ≥10
Number of subjects: 823
Study 38123459 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNGS-high
Number of subjects: 823
Study 38123459 — intervention group
Group type: COMPARATOR
Intervention: IFNGS-low
Number of subjects: 823
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigate intervention (nurse navigation, patient-reported outcomes, physical exercise)
Number of subjects: 11
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse sessions
Number of subjects: 11
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 11
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise sessions
Number of subjects: 11
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of the intervention
Number of subjects: 11
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention
Number of subjects: 11
Study 38123657 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to participation
Number of subjects: 11
Study 38123726 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous spinal direct current stimulation (tsDCS) at 2.5 mA, 3 times/week for 8 weeks
Number of subjects: 20
Study 38123726 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tsDCS
Number of subjects: 20
Study 38123726 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 20
Study 38123759 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cure of primary aldosteronism
Number of subjects: 0
Study 38123762 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush usage after instruction and information
Number of subjects: 170
Study 38123762 — intervention group
Group type: COMPARATOR
Intervention: Self-reported brush usage
Number of subjects: 170
Study 38123789 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 + Endocrine Therapy (ET)
Number of subjects: 382
Study 38123789 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Endocrine Therapy (ET)
Number of subjects: 382
Study 38123866 — intervention group
Group type: EXPERIMENTAL
Intervention: Tu'Washindi intervention
Number of subjects: 103
Study 38123866 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 103
Study 38123875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 1025
Study 38123885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheneau brace and 18 Schroth Best Practice (SBP) exercise sessions
Number of subjects: 30
Study 38123922 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell arm (rituximab reinfused upon B cell repopulation)
Number of subjects: 115
Study 38123922 — intervention group
Group type: COMPARATOR
Intervention: ANCA arm (rituximab reinfused upon significant rise in ANCA level)
Number of subjects: 115
Study 38123922 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell arm
Number of subjects: 115
Study 38123922 — intervention group
Group type: COMPARATOR
Intervention: ANCA arm
Number of subjects: 115
Study 38123922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 115
Study 38123965 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Impedance Cardiography (RIC)
Number of subjects: 127
Study 38123965 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC monitoring for 72 hours
Number of subjects: 127
Study 38123965 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC monitoring
Number of subjects: 127
Study 38123994 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 144
Study 38123994 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (PPL)
Number of subjects: 144
Study 38123994 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) and Propranolol (PPL)
Number of subjects: 144
Study 38124076 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI group
Number of subjects: 30
Study 38124076 — intervention group
Group type: COMPARATOR
Intervention: Control group (minor orthopedic injuries)
Number of subjects: 30
Study 38124084 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia
Number of subjects: 168
Study 38124084 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anaesthesia
Number of subjects: 168
Study 38124088 — intervention group
Group type: EXPERIMENTAL
Intervention: AdDIT trial participants from Canada
Number of subjects: 629
Study 38124088 — intervention group
Group type: EXPERIMENTAL
Intervention: AdDIT trial participants from the UK
Number of subjects: 629
Study 38124088 — intervention group
Group type: EXPERIMENTAL
Intervention: AdDIT trial participants from Australia
Number of subjects: 629
Study 38124098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron treatment during early pregnancy
Number of subjects: 0
Study 38124098 — intervention group
Group type: COMPARATOR
Intervention: Oral iron treatment during early pregnancy
Number of subjects: 0
Study 38124098 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of offspring from previously randomized mothers
Number of subjects: 0
Study 38124112 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazikumab (210 mg) administered subcutaneously every 4 weeks for 100 weeks
Number of subjects: 104
Study 38124133 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) STI testing
Number of subjects: 268
Study 38124133 — intervention group
Group type: COMPARATOR
Intervention: STI syndromic management
Number of subjects: 268
Study 38124133 — intervention group
Group type: EXPERIMENTAL
Intervention: STI diagnosis (positive STI test or reporting STI symptoms)
Number of subjects: 268
Study 38124155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy only (PPV)
Number of subjects: 0
Study 38124155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with scleral buckle (PPV-SB)
Number of subjects: 0
Study 38124155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride gas (SF6)
Number of subjects: 0
Study 38124155 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38124205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP <140mmHg within 30 min)
Number of subjects: 2053
Study 38124205 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management
Number of subjects: 2053
Study 38124205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 2053
Study 38124230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial tenecteplase
Number of subjects: 0
Study 38124230 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 38124481 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 and paxalisib combination treatment
Number of subjects: 0
Study 38124508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral swabs collected from participants with early syphilis
Number of subjects: 32
Study 38124508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion swabs collected from participants with early syphilis
Number of subjects: 32
Study 38124508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral shedding in participants aged 18-29 years
Number of subjects: 32
Study 38124528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg orally once daily
Number of subjects: 961
Study 38124551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel (mean daily dose of 4 mg/day)
Number of subjects: 200
Study 38124551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 200
Study 38124555 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-acetaminophen 1,000 mg (two 500 mg tablets)
Number of subjects: 660
Study 38124555 — intervention group
Group type: EXPERIMENTAL
Intervention: ES-acetaminophen 1,000 mg (two 500 mg caplets)
Number of subjects: 660
Study 38124555 — intervention group
Group type: EXPERIMENTAL
Intervention: LG-ibuprofen 400 mg (two 200 mg capsules)
Number of subjects: 660
Study 38124555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 38125031 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stents (PF-SES)
Number of subjects: 1456
Study 38125301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower free triiodothyronine (fT3) levels in patients with ACLD
Number of subjects: 297
Study 38125301 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone (TSH) levels
Number of subjects: 297
Study 38125301 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 297
Study 38125337 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acupressure educational materials
Number of subjects: 159
Study 38125671 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 669
Study 38125671 — intervention group
Group type: COMPARATOR
Intervention: VEH-PDT
Number of subjects: 669
Study 38125672 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-spin PRP preparation (3,000rpm for 15 minutes)
Number of subjects: 30
Study 38125672 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-spin PRP preparation (first spinning at 1,500rpm for 6 minutes, continuing at 2,500rpm for 15 minutes)
Number of subjects: 30
Study 38125722 — intervention group
Group type: EXPERIMENTAL
Intervention: LTX-315 and adoptive T-cell therapy
Number of subjects: 6
Study 38125722 — intervention group
Group type: EXPERIMENTAL
Intervention: LTX-315
Number of subjects: 6
Study 38125950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian intravoxel incoherent motion (IVIM) model
Number of subjects: 17
Study 38125950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian IVIM model
Number of subjects: 17
Study 38125950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular proliferative activity marker Ki-67
Number of subjects: 17
Study 38125963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412
Study 38125963 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 6412
Study 38126083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 221
Study 38126083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 38126083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 221
Study 38126083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine, placebo, and cognitive behaviour therapy
Number of subjects: 221
Study 38126181 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line Combined Technique (CoT)
Number of subjects: 362
Study 38126181 — intervention group
Group type: COMPARATOR
Intervention: First-line Stent Retriever
Number of subjects: 362
Study 38126183 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate treatment
Number of subjects: 381
Study 38126183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 38126414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 88
Study 38126414 — intervention group
Group type: COMPARATOR
Intervention: Control (no oxytocin induction)
Number of subjects: 88
Study 38126605 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting group (T1)
Number of subjects: 120
Study 38126605 — intervention group
Group type: COMPARATOR
Intervention: Non-waiting group (T0)
Number of subjects: 120
Study 38126709 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone 192 mg
Number of subjects: 12
Study 38126709 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone 384 mg
Number of subjects: 12
Study 38126709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 12
Study 38126709 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX levels < 2 ng/mL
Number of subjects: 12
Study 38126718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature platelet fraction (IPF)
Number of subjects: 108
Study 38126718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature platelet count (IPC)
Number of subjects: 108
Study 38126764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib 3 or 4 mg daily together with metformin once to three times daily (500-1,500 mg).
Number of subjects: 30
Study 38126958 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus panel approach using 3 liver fellowship-trained pathologists scoring histologic parameters.
Number of subjects: 100
Study 38126958 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpanel scoring by 3 trained pathologists.
Number of subjects: 100
Study 38126958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis scoring by trained pathologists.
Number of subjects: 100
Study 38127014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieta Dash application (30 days of use)
Number of subjects: 222
Study 38127015 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrite 40 mg 3 times daily
Number of subjects: 92
Study 38127015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 38127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 0 days
Number of subjects: 3
Study 38127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 1 day
Number of subjects: 3
Study 38127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 2 days
Number of subjects: 3
Study 38127032 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis materials stored for 3 days
Number of subjects: 3
Study 38127049 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated NT-proBNP measurements
Number of subjects: 894
Study 38127049 — intervention group
Group type: COMPARATOR
Intervention: Single NT-proBNP measurement
Number of subjects: 894
Study 38127129 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-dependent PBPK model for acetone and toluene with optimized alveolar ventilation (Qp) parameter.
Number of subjects: 0
Study 38127129 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-dependent Qp relationship integrated into the PBPK toluene model.
Number of subjects: 0
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish Children Healthy Eating Index (FCHEI)
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vegetable oils and vegetable-oil-based margarine (≥ 60% fat)
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of high-fiber grain products
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of sugary products
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable, fruit, and berry consumption
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of low fat (< 1%) milk
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of high-fat (≥ 1%) milk
Number of subjects: 403
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sausage consumption
Number of subjects: 403